IONS - Ionis Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
62.74
+0.64 (+1.03%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close62.10
Open62.30
Bid0.00 x 800
Ask0.00 x 900
Day's Range61.67 - 63.07
52 Week Range44.52 - 86.58
Volume818,256
Avg. Volume1,037,456
Market Cap8.815B
Beta (3Y Monthly)1.64
PE Ratio (TTM)22.10
EPS (TTM)2.84
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.93
Trade prices are not sourced from all markets
  • TheStreet.com

    Ionis Jumps After Vote of Confidence in Drug Pipeline

    A Wells Fargo analyst sees big potential in Ionis' new pipeline of drugs based on antisense oligonucleotide technology, which could prove key in the battle against ALS.

  • Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
    PR Newswire

    Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting

    - Ionis scientists, including CEO Stanley Crooke, M.D., Ph.D., recognized with prestigious Paper of the Year Award for their work on advancing core antisense research - Ionis' Holly Kordasiewicz, Ph.D., ...

  • Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates
    Zacks

    Biotech Stock Roundup: GILD's Descovy Label Expansion Gets FDA Nod & Other Updates

    Key highlights of the past week include label expansion of drugs, licensing deals and more.

  • Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
    PR Newswire

    Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results

    Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results. IONIS-FXI-LRx is an antisense medicine being developed to treat patients with clotting disorders. IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.

  • How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume
    Investor's Business Daily

    How A Deal With Pfizer Sent This Pharma Stock Rocketing In High Volume

    Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.

  • Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers?
    Simply Wall St.

    Does Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Pay Compare Well With Peers?

    Stan Crooke became the CEO of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in 1989. This analysis aims first to contrast...

  • GlobeNewswire

    Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS) and Pfizer Inc. (PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. “AKCEA-ANGPTL3-LRx has the potential to treat people suffering from certain cardiovascular and metabolic diseases.

  • With eyes on IPO, muscular dystrophy startup names new CEO
    American City Business Journals

    With eyes on IPO, muscular dystrophy startup names new CEO

    The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Dyne’s current CEO, Romesh Subramanian, will be replaced by Joshua Brumm, who is leaving his post as CFO of Lexington microbiome startup Kaleido Biosciences and who has taken a California startup public.

  • Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
    Zacks

    Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

    Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

  • Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
    PR Newswire

    Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year

    CARLSBAD, Calif., Sept. 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California's life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year. The award recognizes Ionis' ongoing commitment to growing the life sciences sector in Southern California and for achieving the approval and commercialization of SPINRAZA®, TEGSEDI® and WAYLIVRA® in major markets around the world. The award will be presented at CLSA's 16th Annual Pantheon DiNA™ Awards ceremony Nov. 15, in San Francisco, Calif.

  • MarketWatch

    Akcea's stock drops after 3 top executives leave company, including CEO

    Shares of Akcea Therapeutics Inc. sank 10% in morning trade Monday, after the biopharmaceutical company three of its top executives were leaving the company, including Chief Executive Paula Soteropoulos, effective immediately. The others leaving were President Sarah Boyce and Chief Operating Officer Jeff Goldberg. The company, which is a majority-owned affiliate of Ionis Pharmaceuticals Inc. , said it named Damien McDevitt as interim-CEO. McDevitt was previously chief business officer at Ionis. Akcea said Michael Yang and Joseph Klein have jointed its board of directors. Ionis shares tacked on 0.3%. Over the past 12 months, shares of Akcea have tumbled 27.8%, Ionis have rallied 28.0% and the S&P 500 has gained 2.0%.

  • Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
    Zacks

    Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

    Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.

  • GlobeNewswire

    Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    Biogen Inc. (BIIB) today announced updates to the SPINRAZA (nusinersen) clinical development program including the initiation of a new global clinical trial, DEVOTE. The DEVOTE study will evaluate if a higher dose of SPINRAZA can provide even greater efficacy in the treatment of spinal muscular atrophy (SMA) across a broad patient population.

  • PR Newswire

    Positive preliminary results from ATL1102 for DMD Phase II trial

    MELBOURNE, Australia, Sept. 17, 2019 /PRNewswire/ -- Antisense Therapeutics ("ANP" or the "Company") is pleased to advise that a review of the preliminary data from the 6 patients who have completed their 24 weeks of dosing in the Phase II clinical trial of ANP's immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) therapy, is indicative of a positive drug effect of ATL1102 at the dose tested both at an immunomodulatory (i.e.

  • GlobeNewswire

    Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    BOSTON and CARLSBAD, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) --  Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), presented data today from the Phase 1 clinical trial of AKCEA-TTR-LRx in a poster presentation at the Heart Failure Society of America 23rd Annual Scientific Meeting in Philadelphia, Pennsylvania. AKCEA-TTR-LRx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) technology platform.

  • If You Had Bought Ionis Pharmaceuticals (NASDAQ:IONS) Shares Three Years Ago You'd Have Made 107%
    Simply Wall St.

    If You Had Bought Ionis Pharmaceuticals (NASDAQ:IONS) Shares Three Years Ago You'd Have Made 107%

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...

  • Barrons.com

    How Biotech Companies Are Targeting RNA to Cure Diseases

    For a number of companies, the key isn’t at the DNA level, where the gene therapy players focus, but in the RNA.

  • GlobeNewswire

    Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the NEURO-TTR open-label study along with data from the AKCEA-TTR-LRx program and additional clinical presentations on the efficacy and safety profile of TEGSEDI will be presented at the 2nd European ATTR Amyloidosis Alliance Meeting in Berlin, Germany, September 2-3, 2019.

  • Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo
    Zacks

    Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo

    Ionis (IONS) out-licenses antisense medicines to Glaxo for treating chronic hepatitis B virus infection. Glaxo exercises its option to in-license the same. Shares fall.

  • Ionis Pharmaceuticals to present at upcoming investor conferences
    PR Newswire

    Ionis Pharmaceuticals to present at upcoming investor conferences

    Details on presentation times or changes to presentation dates can be found on the Company's website. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.

  • Ionis licenses hepatitis B program to GSK
    PR Newswire

    Ionis licenses hepatitis B program to GSK

    CARLSBAD, Calif., Aug. 27, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus (CHB) infection following positive Phase 2 results. Current treatments for patients with CHB provide low levels of hepatitis B virus S antigen seroclearance, leaving many patients without a treatment to achieve sustained disease remission. "By targeting the root cause of CHB-related liver disease, our antisense technology can potentially deliver a transformative medicine for people who suffer from chronic hepatitis B virus infection," said Brett P. Monia, chief operating officer at Ionis.

  • GuruFocus.com

    Ionis Pharmaceuticals Inc (IONS) Chairman and CEO Stanley T Crooke Sold $1.6 million of Shares

    Chairman and CEO of Ionis Pharmaceuticals Inc (30-Year Financial, Insider Trades) Stanley T Crooke (insider trades) sold 22,000 shares of IONS on 08/21/2019 at an average price of $71.52 a share. Continue reading...

  • Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript

    IONS earnings call for the period ending June 30, 2019.

  • Ionis Pharmaceuticals Looks to Partners to Pay the Bills
    Motley Fool

    Ionis Pharmaceuticals Looks to Partners to Pay the Bills

    Royalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.